GleamWall
中文EN

KYMR Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%

Returns

ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M
Cost of revenue$0$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M
Gross profit$0$0$0$0$0$0$0$0
R&D expense$128.51M$119.48M$98.16M$83.83M$74.09M$78.39M$80.25M$71.82M
SG&A expense$18.72M$21.13M$20.36M$16.93M$17.34M$17.64M$16.27M$16.33M
Operating income-$147.23M-$75.61M-$84.15M-$97.90M-$92.52M-$84.56M-$74.43M-$80.75M
Net income-$132.00M-$61.21M-$69.23M-$86.98M-$82.17M-$76.61M-$65.58M-$70.75M
EBITDA-$145.63M-$74.01M-$82.13M-$95.86M-$90.82M-$82.86M-$72.38M-$78.77M
EPS (basic)-1.32-0.62-0.71—-0.94-0.95-0.82—
EPS (diluted)-1.32-0.62-0.71—-0.94-0.95-0.82—
Weighted avg. shares (diluted)100.10M98.18M97.53M—87.30M80.45M80.15M—
Balance sheet
Cash & equivalents$373.37M$124.48M$144.09M$357.01M$112.95M$335.82M$89.97M$120.26M
Short-term investments$597.84M$566.51M$506.84M$491.26M$392.73M$329.63M$373.18M$368.49M
Receivables—$20.00M—$0—$40.00M—$0
Current assets$998.59M$737.26M$677.43M$871.21M$528.30M$728.33M$500.95M$510.27M
PP&E, net$38.24M$39.97M$41.62M$43.17M$45.13M$48.57M$49.17M$50.46M
Total assets$1.77B$1.65B$1.67B$1.74B$1.10B$1.13B$918.31M$978.03M
Current liabilities$89.72M$71.33M$62.64M$83.21M$71.58M$87.54M$58.99M$67.77M
Total liabilities$152.74M$136.19M$129.38M$163.15M$155.79M$159.59M$132.08M$142.42M
Shareholders' equity$1.61B$1.51B$1.54B$1.58B$946.26M$971.48M$786.23M$835.62M
Shares outstanding85.33M82.79M82.18M81.32M71.74M70.56M65.11M64.89M
Cash flow statement
Operating cash flow-$77.91M-$54.06M-$88.84M-$66.75M-$27.11M-$59.88M-$79.15M-$61.78M
Capital expenditure$315,000$473,000$434,000$106,000$181,000$695,000$467,000$936,000
Free cash flow-$78.23M-$54.54M-$89.27M-$66.85M-$27.29M-$60.58M-$79.62M-$62.72M
Investing cash flow$101.63M$20.05M-$142.84M-$394.40M-$235.30M$60.02M$48.62M$68.57M
Financing cash flow$225.57M$14.42M$18.77M$705.22M$39.51M$245.73M$258,000$2.77M
Depreciation & amortization$1.60M$1.60M$2.02M$2.03M$1.70M$1.70M$2.05M$1.99M
Stock-based compensation$18.84M$18.94M$16.01M$14.45M$15.80M$15.41M$14.23M$13.80M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.